Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROGRESS: Atogepant for Prevention of Chronic Migraine
2018-004337-32Phase 3Completed
- Sponsor
- Allergan
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atogepant in chronic migraine (3 arms), sponsored by Allergan. Primary endpoint: Change from baseline in mean monthly migraine days. Started Jul 2019; status: completed.
02
Drugs
atogepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2018-004337-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004337-32.